Clinical trials are experiments designed to test the safety and efficacy of new treatments or interventions in a controlled setting. The results of these trials are used to make decisions about whether or not to approve new drugs or treatments for use in the general population.
However, it’s important to recognize that the results of clinical trials may have limitations when it comes to their generalizability to the larger population. This is because clinical trials are typically conducted under controlled conditions, which may not accurately reflect the real-world conditions in which the treatment or intervention will be used.
Some of the limitations of clinical trial results in terms of generalizability to the larger population include:
Limited patient population: Clinical trials often have strict inclusion and exclusion criteria, which can limit the types of patients who are eligible to participate. This means that the results may not be generalizable to patients who do not meet these criteria.
Short follow-up time: Clinical trials are often conducted over a relatively short period of time, which may not be long enough to capture the long-term effects of the treatment or intervention.
Controlled setting: Clinical trials are conducted in a controlled setting, which may not accurately reflect the real-world conditions in which the treatment or intervention will be used.
Selective reporting [Controversial]: Clinical trial results may be subject to selective reporting, where only the most favorable outcomes are reported, while negative results are suppressed.
Real-world evidence (RWE) refers to data collected outside of clinical trials, such as data from electronic health records, insurance claims, and patient registries. RWE can provide important insights into how treatments or interventions work in real-world settings, and can help to address some of the limitations of clinical trial results in terms of generalizability.
However, it’s important to recognize that RWE also has its own limitations, such as the potential for confounding and bias, as well as issues related to data quality and completeness. Therefore, it’s important to carefully consider the limitations and potential biases of both clinical trial results and real-world evidence when making decisions about treatments or interventions for the larger population.
Share this story...
Real World Evidence (RWE) 101 – Is ‘Retrospective Data’ the Same as ‘Secondary Use of Existing Data’?
RWE 101 - Is 'Retrospective Data' the Same as 'Secondary Use of Existing Data'? Retrospective data generally refers to data that has already been collected for another purpose [...]
Real World Evidence (RWE) 101 – EHDS and GDPR – How does GDPR support the secondary use of existing health data for the purposes of scientific research?
RWE 101 - EHDS and GDPR - How does GDPR support the secondary use of existing health data for the purposes of scientific research? The GDPR (General Data [...]
Real World Evidence (RWE) 101 – Federated Clinical Data
RWE 101 - Federated Clinical Data Federated clinical data refers to clinical data that is distributed across multiple organizations or entities, such as hospitals, clinics, research institutions, [...]
Real World Evidence (RWE) 101 – The European Health Data Space (EHDS)
RWE 101 - The European Health Data Space (EHDS) The European Health Data Space (EHDS) is a proposed initiative by the European Union to create a secure and [...]
Real World Evidence (RWE) 101 – The Impact of the EMAs Data Quality Framework on RWE
RWE 101 - The Impact of the EMAs Data Quality Framework on RWE The EMA (European Medicines Agency) data quality framework provides a set of guidelines and principles [...]
Real World Evidence (RWE) 101 – DARWIN-EU
RWE 101 - DARWIN-EU DARWIN-EU is a project that aims to establish a sustainable platform for generating and using real-world evidence (RWE) to support decision-making in healthcare [...]







